Euclises Pharmaceuticals Financing
Euclises Pharmaceuticals, Inc., Corporation just submitted form D because of $2.71 million equity financing. The date of first sale was 2015-11-09. Euclises Pharmaceuticals was able to sell $1.22 million so far. That is 44.88% of the offering. The total fundraising amount was $2.71 million. The form was filed on 2016-12-01. The reason for the financing was: unspecified. The fundraising still has about $1.49 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Euclises Pharmaceuticals is based in Missouri. The firm’s business is Pharmaceuticals. The form D was submitted by Bobby W Sandage Jr President and CEO. The company was incorporated in 2011. The filler’s address is: 4320 Forest Park Avenue, Suite 303, St. Louis, Mo, Missouri, 63108. Robert A. Beardsley is the related person in the form and it has address: 4320 Forest Park Avenue, Suite 303, St. Louis, Mo, Missouri, 63108. Link to Euclises Pharmaceuticals Filing: 000155035016000003.
Analysis of Euclises Pharmaceuticals Offering
On average, firms in the Pharmaceuticals sector, sell 60.90% of the total offering size. Euclises Pharmaceuticals sold 44.88% of the offering. The financing is still open. The average fundraising amount for companies in the Pharmaceuticals industry is $556,000. The total amount raised is 118.87% bigger than the average for companies in the Pharmaceuticals sector. The minimum investment for this offering was set at $1. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Euclises Pharmaceuticals Also
The Form D signed by Bobby W Sandage Jr might help Euclises Pharmaceuticals, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.